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VascularizationWhile numerous lines of evidence point to increased levels of oxidative stress playing a causal role in a num-
ber of neurodegenerative conditions, our current understanding of the speciﬁc role of oxidative stress in the
genesis and/or propagation of neurodegenerative diseases remains poorly deﬁned. Even more challenging to
the “oxidative stress theory of neurodegeneration” is the fact that many antioxidant-based clinical trials and
therapeutic interventions have been largely disappointing in their therapeutic beneﬁt. Together, these factors
have led researchers to begin to focus on understanding the contribution of highly localized structures, and
deﬁned anatomical features, within the brain as the sites responsible for oxidative stress-induced neurode-
generation. This review focuses on the potential for oxidative stress within the cerebrovascular architecture
serving as a modulator of neurodegeneration in a variety of pathological settings. In particular, this review
highlights important implications for vascular-derived oxidative stress in the initiating and promoting path-
ophysiology in the brain, identifying new roles for cerebrovascular oxidative stress in a variety of brain dis-
orders. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
Published by Elsevier B.V.1. Introduction
The brain accounts for ~2% of total body mass, but requires ~20%
of the total blood ﬂow from the heart to supply the cells of the
brain with continual fresh oxygen and energy for the maintenance
of homeostasis [1]. The exquisite vascular network within the brain
accomplishes this delivery of oxygen and gasses, as well as the re-
moval of numerous potentially toxic molecules, via a continual and
seamless perfusion of the entire brain [2]. The selectivity of the
blood brain barrier (BBB) allows some molecules to move between
the peripheral circulation into the brain, and vice versa, all the
while assisting in maintaining homeostasis for the neurons, glia, and
vascular cells in the immediate area of the BBB [2,3].
As pointed out in numerous reviews within this collection, there is
little doubt that increased levels of oxidative stress occurs in condi-
tions where neurodegeneration is observed. There are almost an un-
limited number of studies, in a plethora of settings, which ﬁrmly
establish evidence for oxidation to proteins, lipids, sugars, and nucleic
acids occurring in most (if not all) neurodegenerative conditions. An
equally large number of studies have demonstrated oxidative stress
occurs in the earliest stages of these conditions, and tightly correlates
with the development of motor and cognitive disturbances [4–6]. Inants and Antioxidant Treatment
esearch Center, 6400 Perkins
90; fax: +1 225 763 3193.
.V.contrast to this strong level of association, many questions remain
in regards to whether oxidative stress is a cause or consequence of
neurodegenerative processes. This is largely based on the relatively
non-speciﬁc and ubiquitous nature of oxidative stress in these differ-
ent settings. Furthermore, current antioxidant-based therapies for the
treatment and/or management of neurodegenerative diseases in clin-
ical settings (randomized and epidemiological) and rodent studies,
have identiﬁed antioxidant based therapies to be largely ineffective
[4,5].
The premise of this review is that the cerebrovasculature may be
an important source, and target, of oxidative stress in the brain. We
believe that the very factors which allow the vasculature to conduct
its vital functions for the brain predispose it to oxidative stress. For
example, while only accounting for small global elevations in oxida-
tive stress, localized increases in the levels of oxidative damage with-
in the vasculature may be sufﬁcient to promote deleterious changes
in blood-ﬂow, BBB integrity, and serve as an initiator for numerous
lines of pathogenesis in the brain. If our model is correct, such data
would have important implications for not only understanding oxida-
tive stress, but may lead to the development of novel antioxidant
strategies for numerous disorders.
This review will deﬁne oxidative stress, as well as outline the nu-
merous neurodegenerative disorders associated with oxidative stress
and vascular pathogenesis. Additionally, this review will outline what
is known in regards to the efﬁcacy of a variety of antioxidant-based
interventions in regards to their use in treatment of neurodegenera-
tive disorders and modulation of pathological processes. The review
will then go into greater detail as to the underlying basis for the
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speciﬁc contribution of how oxidative stress in the vascular compo-
nents of the brain mediates disease pathogenesis. We will then at-
tempt to explain the importance of targeting the vasculature in the
design and deployment of antioxidant-based therapies for the brain
in the future.
1.1. Oxidative stress
An imbalance between cellular pro-oxidants and anti-oxidants
can occur during aging as well as during many age-related diseases
of the central nervous system [7]. This phenomenon is referred to as
oxidative stress, and is induced by highly reactive oxygen species
(ROS) and reactive nitrogen species (RNS) that possess an unpaired
electron [4]. All macromolecules in the cell are vulnerable to oxidative
damage, including lipids, proteins, and nucleic acids [8]. However,
cells are equipped to counteract this oxidative attack with numerous
cellular antioxidant defenses such as glutathione (GSH), superoxide
dismutases, and catalase [9]. During aging and various disease states,
these antioxidant defense systems can be altered leading to progres-
sive oxidative damage and subsequent cell death and/or signiﬁcant
loss of function [6]. Changes in antioxidant status within speciﬁc
cells and structures of the brain may be particularly useful in dictating
whether oxidative stress is benign or pathological.
1.2. Diseases of the nervous system: oxidative stress
Oxidative stress has been implicated in numerous diseases of the
nervous system such as (but not limited to): Alzheimer's disease
(AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS), HIV-associated neurocognitive disorder
(HAND or “NeuroAIDS”), cerebral ischemia/reperfusion injury (I/R),
and traumatic brain injury (TBI). In these disease states, oxidative
stress has been implicated in playing an early, initiating role as well
as a potentially late, by-product of neurodegeneration.
In the case of AD, oxidative stress is proposed to be an early event
that aids in progressive neurodegeneration and subsequent cognitive
impairment [10–12]. One of the contributing factors that is common
to many neurodegenerative diseases involving oxidative stress path-
ways is mitochondrial dysfunction [12–16]. It has previously been
shown that neurons in the AD brain exhibit damaged mitochondria,
speciﬁcally altered α-ketoglutarate dehydrogenase complex
(KGDHC) and pyruvate dehydrogenase complex (PDHC) which
leads to increased ROS production [17–19]. In addition, components
of the β-amyloid (Aβ) processing machinery are found in mitochon-
dria and it has been shown that Aβ accumulates in the mitochondrial
matrix leading to toxicity and increased release of ROS [20,21]. The
interaction between Aβ toxicity and increased oxidative stress has a
large impact on AD pathology [16]. Not only does Aβ accumulate in
mitochondria, but as it deposits throughout certain areas of the
brain, microglia and astrocytes also cluster at these sites leading to
“hot spots” of inﬂammation and production of ROS/RNS [22]. Speciﬁ-
cally, the Aβ peptide can activate microglial NADPH oxidase (NOX)
which increases production of superoxide radicals and hydrogen per-
oxide [23,24]. Aβ also interferes with the proteasome by decreasing
proteolytic activity [25–27]; it has been shown in our lab [27] as
well as others [25,28] that inhibition of the proteasome leads to in-
creased oxidative stress. In addition to the inﬂammatory and oxida-
tive stress reactions occurring in the AD brain which have profound
effects on neuronal health, these detrimental effects are also occur-
ring in the brain microvasculature [3]. The combined effects of reac-
tivity from glial cells, cerebral endothelial cells, neurodegeneration,
and BBB disruption during this process provide an environment for
further activation of inﬂammatory and oxidative stress responses
[3,29].Mitochondrial defects are also observed in PD [16]; speciﬁcally, re-
duced activity of the mitochondrial respiratory complex I (NADPH-
quinone oxidoreductase) in the substantia nigra [30] as well as the
frontal cortex [31,32]. It has been shown that oxidative stress causes
damage to the complex I subunits, altering assembly, leading to mito-
chondrial dysfunction and consequently reducing electron transfer
rates and increasing ROS production [31,33]. It is well known that
Parkinson's disease pathology includes the selective loss of dopamine
neurons [34], and it is hypothesized that the main cause of this loss is
the high levels of ROS in dopamine neurons due to dopamine metab-
olism and their high iron content [35]. In support of the role of mito-
chondrial complex I inhibition in PD, various disease models for PD
also involve inhibition of complex I. For example, accidental forma-
tion of the drug 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP) in the late 1970's led to an important animal model of PD
after the drug was self-administered in a number of humans that
quickly displayed Parkinsonian behaviors and pathology [36]. It was
later determined that MPTP gets converted to MPP+by glial cells in
the brain which is neurotoxic, and it is taken up speciﬁcally by the do-
pamine transporter in the substantia nigra dopamine neurons [37].
Interestingly, MPP+binds to the mitochondrial complex I and in-
hibits its activity leading to mitochondrial dysfunction, oxidative
stress and cell loss [34]. Two other PD models that also have effects
on complex I and lead to Parkinsonian behavior/pathology include
the pesticides rotenone and paraquat [38–41]. In addition to mito-
chondrial defects due to complex I, it has been proposed that the
parkin gene (PRKN) plays an important role in PD pathogenesis
[32,42,43]. In juvenile PD especially, a large number of patients exhib-
it mutations in PRKNwhich affects the proteasome andmitochondrial
activity [43]. In experiments with parkin-deﬁcient mice, increased
protein oxidation, increased lipid peroxidation and decreased mito-
chondrial respiratory capacity have been observed [44]. On the
other hand, overexpression of parkin reduces ROS, enhances complex
I activity and increases the mitochondrial membrane potential, point-
ing to an important role of parkin in mitochondrial performance [45].
Lastly, and similar to ﬁndings for Aβ in AD, the aggregated protein, α-
synuclein found presynaptically in PD brains affects mitochondria and
increases oxidative stress [46]. While PD exhibits some similar path-
ways for degeneration as AD, the role of oxidative stress at cerebral
endothelial cells has not yet been explored for PD pathogenesis; we
argue this is an important source of oxidative stress in neurodegener-
ative diseases including PD.
Similar to AD and PD, mitochondrial injury plays a role in MS pro-
gression [47]. However, the major source for free radical production is
thought to be stimulated by chronic inﬂammation and the release of
toxic radicals by activated microglia [48,49]. ROS and RNS can specif-
ically affect mitochondrial complex IV of the respiratory chain, which
has been shown in axons, oligodendrocytes and astrocytes of MS pa-
tients [50]. When this occurs in axons, transport is disturbed due to a
loss of energy and when this occurs in oligodendrocytes, apoptosis
follows [51]. Results are controversial but some laboratories have
shown oxidized DNA and lipids within active lesions, also pointing
to the role of oxidative stress in MS [47,52,53]. The large focus of
MS research is at axons and oligodendrocytes due to their obvious
role in disease progression, however we argue the potential role of
cerebral endothelial cells in contributing to inﬂammation and oxida-
tive stress at these sites. This must be further investigated as another
potential source for the observed damage.
Much less is known about the source of oxidative stress found in
ALS and HAND. In 20% of familial ALS (about 2% of all cases), a muta-
tion in the copper–zinc superoxide dismutase (SOD1) gene was found
and hypothesized to alter axonal transport of mitochondria, especial-
ly to distal nerve terminals [54,55]. Expression of mutant SOD1 has
been observed in the cytoplasm, nucleus, endoplasmic reticulum
and intramembrane space of mitochondria, providing sites where
oxidative damage likely occurs [56]. Unfortunately, sporadic ALS
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cases reveal dense clusters of mitochondria that have accumulated
in the anterior horn of the lumbar spinal cord, which may contribute
to oxidative stress and subsequent degeneration [54,57,58]. However,
more studies must be performed to understand the mechanisms for
oxidative stress production in ALS, especially the sporadic cases. The
etiology of HAND is also not currently well understood. However,
similar to MS, it is thought that increased inﬂammation and ensuing
activated microglia play a key role in stimulating production of ROS;
inﬂammation and oxidative stress together can contribute to neuro-
degeneration and subsequent cognitive decline [59,60]. As with the
other neurodegenerative diseases brieﬂy reviewed herein, the role
of cerebral endothelial cells in promoting oxidative stress and subse-
quent disease progression has not yet been well explored for ALS or
HAND; we hypothesize it to play a role in these neurodegenerative
diseases and it must be further examined.
Lastly, I/R and TBI have clear mechanisms for ROS production,
which also contribute to BBB disruption. In both cases, a large inﬂux
of hemoglobin (during reperfusion in I/R and due to mechanical inju-
ry in TBI) leads to the increased presence of iron to stimulate free
radical production [61–63]. Both cases also involve mitochondrial
dysfunction and increased microglial activation, as previously de-
scribed [64,65]. Another interesting factor in both of these injuries is
the breakdown of the BBB which provides a cycle of damage: in-
creased production of ROS and then further breakdown of the BBB
from oxidative stress [65,66]. The unique features of the BBB that
can protect against oxidative stress and those features that in fact
cause it to be susceptible to oxidative stress are described below.
1.3. The blood brain barrier and oxidative stress
Capillaries found in the central nervous system are distinct from
those found in the rest of the body due to the BBB, an important ﬁlter
that protects the brain [67,68]. Features of the BBB include tight junc-
tion proteins that “glue” together the cerebral endothelial cells, such
as occludin, claudins, and junction adhesion molecules (JAMs) [69].
These proteins are then anchored in the endothelial cells by scaffold-
ing proteins such as the zona occludens (ZO-1, ZO-2, ZO-3) [69].
Another protective layer is provided by a thick basement membrane
and astrocytic end feet [69].
In addition to these protective layers, cerebral endothelial cells are
equipped with a defense system against oxidative stress including in-
creased GSH, glutathione peroxidase, glutathione reductase and cata-
lase compared to the rest of the brain [9]. GSH in particular has been
shown to play an important role in maintenance of BBB integrity [70].
All areas of the healthy brain also consist of antioxidants such as
superoxide dismutase (SOD) in order to provide a balance against
the high concentration of ROS and RNS produced [71]. Manganese-
containing SOD (MnSOD) is found in the mitochondrial matrix
while copper- and zinc-containing SOD (CuZnSOD) is found mostly
in the cell cytosol [72]. These enzymes aid in the conversion of O2−
to H2O2, which is also a ROS, but it is removed by catalase (and
other enzymes) that are found in most tissues [71]. Through this con-
version, the production of ONOO− (peroxynitrite) is reduced. With-
out this system, peroxynitrite can rapidly form due to high
concentrations of NO, particularly at the endothelial cells [73].
Lastly, throughout the body, NF-erythroid 2-related factor 2 (Nrf2)
plays a key role in defense against oxidative stress. It has previously
been shown that Nrf2 is important for ischemic lesion repair and
new studies are focusing on this transcription factor for therapies
against neurodegenerative diseases such as Parkinson's disease [74].
Under basal conditions, Nrf2 is anchored to the cytoplasm by Kelch-
like ECH-associated protein 1 (Keap1) [75]. However, when oxidative
stress occurs, the cysteine residues of Keap1 become oxidized, releas-
ing Nrf2 to enter the nucleus. There, it binds to the antioxidant
response element (ARE) of many different genes, allowingtranscription of antioxidants [74,75]. It is also believed to increase
anti-inﬂammatory mediators, activity of the proteasome and other
transcription factors involved in mitochondrial biogenesis [74].
Therefore, the brain is well-equipped with a number of antioxidant
properties to stave off oxidative stress.
On the other hand, there are a number of factors inherent to the
brain and cerebral endothelial cells that increase opportunities for ox-
idative stress. First, the brain uses a lot of oxygen (20% of the body's
basal levels) [1]. Neurons require a high amount of ATP for maintain-
ing their membrane potential, packaging neurotransmitters and re-
leasing neurotransmitters; this requires a high level of activity from
mitochondria and therefore, high oxygen consumption [4]. With an
increased presence of oxygen, comes an increased chance for reactive
oxygen species production. The brain also contains nitric oxide, in-
creasing the opportunity for RNS production, such as peroxynitrite
[76]. Nitric oxide (NO) or endothelium-derived relaxing factor
(EDRF) is not only found in the brain for neurotransmission, but at
the cerebral endothelial cells for vasodilation as well [77]. Next, the
neuronal membrane is largely made up of polyunsaturated fatty
acids (PUFAs), especially docosahexaenoic acid [4]. PUFAs in particu-
lar are highly susceptible to lipid peroxidation. For example, 4-
hydroxynonenal (HNE) is produced from lipid peroxidation and has
been shown to be cytotoxic to neurons [78]. High levels of HNE
have been reported in numerous neurodegenerative diseases [78–
80]. Cerebral endothelial cells also have a high concentration of mito-
chondria, providing an increased opportunity for generating oxida-
tive stress [3]. However, this high concentration of mitochondria is
also believed to play a role in BBB maintenance. For example, the
BBB performs energy-dependent transport mechanisms that require
the function of many mitochondria [3]. With aging, a decrease in mi-
tochondrial number at cerebral endothelial cells and subsequent loss
of BBB integrity has been reported [81]. Therefore, a number of fea-
tures that have evolved for the high-level functioning of the BBB
and cerebral endothelial cells themselves also come at a price, with
the prospect for producing oxidative stress. Some of these factors
are displayed in Fig. 1.
Lastly, the properties described herein that can increase oxidative
stress not only lead to neurodegeneration and breakdown of the BBB
via disruption of tight junction proteins, but can alter blood ﬂow as
well [82]. This interaction is complex, particularly for O2− which can
cause relaxation as well as contraction of cerebral blood vessels
depending on the concentration and presence of other species [82].
For example, in the presence of NADPH, contraction occurs but
when O2− is produced from xanthine, dilatation occurs [82]. When
O2− inactivates NO, a loss of vasodilation is observed [83]. H2O2 also
has varying effects: in lower concentrations, dilation occurs [84] and
in high concentrations, the vasodilation is preceded by a period of va-
soconstriction [82,85]. Altogether, the brain, particularly the cerebro-
vascular system, features many sources of producing oxidative stress
as well as targets vulnerable to this stress allowing for a cycle of
damage.
1.4. Therapies designed to combat oxidative stress: pharmaceutical
approaches
As more evidence points to the role of oxidative stress in neurode-
generative disorders, a number of antioxidant-based therapies have
been developed. Unfortunately, there has not been a signiﬁcant
amount of success with these antioxidant treatments in humans.
For this review, we will recount a number of pharmaceutical
approaches and nutritional approaches that have been attempted.
However, this list is not exhaustive for all antioxidant-based therapies.
Selegiline ((R)-N-methyl-N-(1-phenylpropan-2-yl)prop-1-yn-3-
amine) is a selective, irreversible monoamine oxidase B (MAO-B)
inhibitor, when given in low doses [86]. It has been prescribed mostly
for Parkinson's disease patients [86], however, it has also been
Fig. 1. Sources of oxidative stress at cerebral endothelial cells. A) In the healthy brain, the BBB is intact with the help of claudins, occludin, and junctional adhesion molecules (JAMs)
to create the tight junction between endothelial cells. Actin and the zona occludens (ZO-1 and ZO-2, etc.) also create a scaffold for the tight junction. Further support for the BBB
comes from the extracellular matrix and astrocytic end feet. B) In the unhealthy brain, ROS accumulate from various sources including mitochondria, microglia, the lipid bilayer, and
astrocytes. This causes altered assembly of the tight junctions, breakdown of the extracellular matrix by MMPs and subsequent loss of BBB integrity.
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[87,88]. In addition to its effects on the monoamine oxidase system,
the drug has also exhibited antioxidant and neuroprotective effects
[89]. The main mechanisms of action for its antioxidant properties
include reducing oxidative stress products formed during dopamine
catabolism and increasing the activity of superoxide dismutase and
catalase [89]. Unfortunately, the drug (as for all monoamine oxidase
inhibitors) has negative side effects including withdrawal, numerous
drug interactions and interactions with foods that can cause hyper-
tensive crisis [88]. For PD treatment, it has not shown a signiﬁcant ef-
fect when given alone, but in combination with levodopa (L-DOPA),
some improved effects have been observed (reviewed by [90]). How-
ever, this is mainly used to treat early symptoms of PD and is not cu-
rative. Another drug that has been developed mainly for treatment of
PD is nitecapone (OR-462), a selective catechol-O-methyltransferase
(COMT) inhibitor. It also has antioxidant properties including scav-
enging of free radicals such as peroxy radicals and subsequent inhibi-
tion of lipid peroxidation [91]. Again, nitecapone has not displayed
signiﬁcant treatment effects for PD alone, but it has shown efﬁcacy
in combination with L-DOPA [5,92]. While selegiline and nitecapone
exert effects particularly on the dopamine metabolism pathway,
they both exhibit neuroprotection and antioxidant effects. In consid-
ering whether these drugs may also be applied speciﬁcally at the
BBB for reducing cerebral endothelial cell oxidative stress, selegiline
may be the only promising target; selegiline has been shown to
cross the BBB [89], however nitecapone does not [93]. Instead, niteca-
pone exerts its effects mainly on L-DOPA in the periphery [93]. On the
other hand, targeting oxidative stress at the BBB may require action
on both sides of the endothelial cells (within the vasculature and
within the brain). Pharmaceutical antioxidants that can target these
areas must be further investigated in future studies.N-acetylcysteine (NAC) has many proposed uses including treat-
ment of paracetamol overdose [94], drug addiction [95], obsessive-
compulsive disorder [96], diabetic neuropathy [97], as well as many
neurodegenerative disorders: AD, PD, andMS [98]. NAC is a derivative
of cysteine which also exerts antioxidant effects [99]. The mecha-
nisms of action include generation of intracellular GSH [97] and it is
reported to directly scavenge H2O2 and OH− in vitro [100]. It has
also been shown to decrease the lipid peroxidation product, HNE
[101]. While many studies have investigated the various actions and
potential uses of NAC, no successful clinical trials for the treatment of
neurodegenerative disease have been reported at this time. However,
N-acetylcysteine administration has been proposed for various dis-
eases, and it is able to cross the BBB [102], making it an interesting
candidate for application at the cerebral endothelial cells.
Recent clinical trials with edavarone (3-Methyl-1-phenyl-2-
pyrazolin-5-one), a free radical scavenger, have shown some success
for ischemic stroke patients. In a randomized, controlled clinical trial
in India, treatment with edavarone compared to placebo resulted in
improved functional outcome following acute ischemic stroke [103].
In a randomized, controlled clinical trial in Japan, edavarone treat-
ment reduced the volume of infarct and improved neurological deﬁ-
cits following acute ischemic stroke [104]. It has been proposed that
edavarone may be a successful antioxidant therapy in PD as well
since experiments performed in mice have shown protection against
MPTP-induced damage in the substantia nigra. However, these effects
were not observed in the striatum [105]. In comparison to the other
pharmaceutical antioxidants reviewed herein, edavarone appears to
be the most promising for administration at cerebral endothelial
cells and subsequent improvement to BBB disruption. In fact, recent
studies have demonstrated improved BBB integrity following edavar-
one treatment particularly due to its effects on inhibiting MMP-9
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edavarone on the BBB are necessary.
1.5. Therapies designed to combat oxidative stress: dietary approaches
A large collection of antioxidants are available from dietary
sources including: carotenoids, vitamins A, C and E, and polyphe-
nols/ﬂavonoids [109]. Antioxidants are mainly found in fresh fruits,
vegetables, nuts and oils; some of the most well-known antioxidants
include: blueberries, spinach, grapes, red wine, curcumin, and olive
oil; there is an abundant source in the everyday diet. With many ﬁnd-
ings on the role of oxidative stress in disease, both pharmacological
(as described above) and dietary antioxidants have become prospects
for therapeutic development. Unfortunately, most clinical trials have
not been successful; in fact, many trials have even proved harmful.
As reviewed by Edeas [110], numerous clinical trials with dietary
antioxidants for disorders such as cancer (reviewed by [111]), cardio-
vascular disease (reviewed by [112]), and incidence of stroke
(reviewed by [113]) have not shown clinical efﬁcacy to date. Clinical
trials with antioxidants for neurodegenerative diseases such as AD
and PD have provided some optimism, but they are also not currently
at optimal efﬁcacy. As reviewed by Grundman and Delaney [114], it
was ﬁrst determined that certain dietary antioxidants in serum or
plasma are at lower levels in AD patients compared to healthy con-
trols such as vitamin E [115–117], vitamin C [115,116,118], and vita-
min A [115–117,119]. However, these are controversial results as
other studies have found no difference between AD patients and
healthy controls for plasma vitamin E [118], vitamin C [120], and vita-
min A [120]. The subsequent experiments and clinical trials to in-
crease levels of these vitamins have also provided conﬂicting
results. In the Rotterdam study, as reported by Engelhart [121,122],
subjects were interviewed for dietary/lifestyle factors and follow-up
tests included various neurological, metabolic, and cardiovascular
exams. It was determined that subjects with a high dietary intake of
vitamin E and vitamin C, had a decreased risk of developing AD. In a
clinical trial of vitamin C supplements over a four year period, sub-
jects were found to exhibit improved cognitive performance [123].
On the other hand, a recent clinical trial for vitamin E supplementa-
tion in stroke did not show improvement [124]. Furthermore, in a
review by Boothby and Doering [125], it was concluded that vitamin
C and vitamin E supplementation not only showed a lack of improve-
ment for Alzheimer's disease prevalence and incidence, but also in-
creased risk for cardiovascular issues and mortality [125].
It has recently been determined that a necessary balance in dosage
and opportunity for synergism with other antioxidants (endogenous
or given) must be found in antioxidant treatments [126]. For clinical
trials that have actually led to damage, it is believed that the dosage
of antioxidant not only reduces ROS and/or RNS, but can halt proper
cellular activities as well. Oxidative stress is deﬁned as an imbalance
between pro-oxidants and antioxidants [5]; therefore, delivery of too
much antioxidant can still tip the scale to an unfavorable level, leading
to more oxidative stress. As researchers have now determined this
“tightrope” to walk in antioxidant therapy, more attention will be
given towards site-speciﬁc delivery, regulated dosing, and cocktails of
various antioxidants (dietary and/or pharmacological) that may work
synergistically for the proper effect. We argue that the cerebral endo-
thelial cells are an important site for new therapies to be designed.
1.5.1. Proposed mechanisms for damage at the BBB from oxidative stress
One of the most well-studied mechanisms for disruption of the
BBB from oxidative stress is via matrix metalloproteinase (MMP) ac-
tivation. The MMPs are zinc-containing enzymes that degrade extra-
cellular matrix around cerebral blood vessels and neurons [66]. Free
radicals activate MMPs which then stimulates their degradation ac-
tivity; this can occur at the tight junctions and therefore disrupt the
vital barrier [65]. Loss of BBB integrity due to oxidative stress viaMMP activation is a main issue of cerebral ischemia–reperfusion inju-
ry [65]. Therefore, this may be an important target for antioxidant ther-
apies. As mentioned above, the beneﬁcial effects of edavarone as a free
radical scavenger, but also a potential MMP9 inhibitor make it an inter-
esting candidate for delivery at the BBB. Other pharmaceutical and/or
dietary antioxidants with similar effects must also be explored.
NADPH oxidases (NOXs) also play an important role in vascular
oxidative stress as well as BBB disruption [127,128]. The NOX family
(i.e. NOX1, NOX2, NOX3, NOX4) provides a major source of ROS in ar-
terial walls and are implicated in the pathogenesis of hypertension,
hypercholesterolemia, diabetes, aging, cerebral amyloid angiopathy
(CAA) and Alzheimer's disease [128–133]. On one hand, NOXs are
necessary for the regulation of vascular smooth muscle tone, control-
ling endothelium-dependent dilation responses, and cerebrovascular
tone [132]. On the other hand, they are also responsible for disruption
of the BBB particularly during stroke as one of the most powerful pro-
ducers of O2− in the brain and cardiovascular system [64]. Speciﬁcally,
these enzymes transfer electrons from NADPH to oxygen which cre-
ates the superoxide radical [134]. Antioxidants that can act at the
BBB to scavenge these free radicals or pharmaceuticals that can
block the excessive transfer of electrons to oxygen from NADPH
could help to protect the integrity of the BBB.
Another feature described in stroke pathogenesis, but one that
likely plays a role in neurodegenerative conditions as well, is the tox-
icity of circulating free iron. Similar to the features described above,
iron has an essential role in proper brain functioning such as energy
production, protein function, and mitochondrial enzyme function
[135]. In fact, iron is taken up through nutrition and then transported
across the BBB, mainly through the transferrin pathway [63]. However,
when free iron is circulating, it binds oxygen to produce hydroxyl radi-
cals [4]. During stroke, when the BBB is compromised, free plasma iron
can leak into the brain leading to increased oxidative stress and neuro-
nal death [62]. This provides a damaging cycle of cell death and the
opportunity for further degradation of the BBB. Therefore, therapies tar-
geted at scavenging free iron as well as the hydroxyl radicals produced
would be useful for maintaining the BBB.
Arguably, all neurodegenerative conditions involve inﬂammation
and therefore, glial (microglial and/or astrocyte) activation. As de-
scribed for the neurodegenerative disorders above, the activation of
glia acts as a stimulator for oxidative stress. Together, breakdown of
the BBB can occur. Upon activation, glia are capable of releasing O2−,
H2O2, and NO− in addition to cytokines [4]. In fact, certain cytokines
may lead to increased production of ROS and RNS during stimulation.
All of the mechanisms involved in BBB disruption are not currently
understood, however, MMP degradation of tight junction proteins
and lack of astrocytic end feet for support are two ways that glial ac-
tivation contribute. As mentioned previously, drug cocktails are likely
an important method for treating the multifactorial neurodegenera-
tive conditions; therapeutics that include anti-inﬂammatory and anti-
oxidant action seem to be a promising technique.
There are a few neurodegenerative conditions that have already
been described to involve loss of BBB integrity due, at least in part,
to oxidative stress. In hypoxia-reoxygenation, ROS production in-
creases particularly during the reoxygenation phase which can alter
tight junction protein assembly and function leading to leakage of
the BBB [2,136]. As mentioned previously, in Alzheimer's disease, pro-
duction of ROS from various sources including activated microglia
and Aβ plaques also causes a breakdown of the BBB. Finally, in CAA,
which is characterized by Aβ in the blood vessel wall, oxidative stress
is implicated in disease pathogenesis and BBB breakdown, with the
contribution of MMP activation by ROS [133].
2. Summary and future directions
Taken together, these data point to the cerebrovasculature as both a
source, and target of oxidative stress in a variety of neurodegenerative
827L.R. Freeman, J.N. Keller / Biochimica et Biophysica Acta 1822 (2012) 822–829conditions. The causative role of oxidative stress in stroke andmediating
role in stroke pathogenesis has beenwell described. However, relatively
little is known in regards to the contribution of these factors to other
neurodegenerative disorders. Studies in the near future, from our labo-
ratory and others, will identify whether oxidative stress in the vascula-
ture serves as an essential role in propagating neuropathogenesis in
AD and other disorders. In particular, studies are needed to selectively
target the cerebrovasculature for antioxidant-based interventions. Tak-
ing advantage of the unique microenvironment of the BBB and cerebro-
vasculature will likely be the key in identifying the most effective
antioxidant-based interventions for numerous age-related neurodegen-
erative conditions. Preservation of the function of the vasculature via
vessel-targeted antioxidants will ensure sufﬁcient tissue perfusion,
maintenance of BBB integrity, and the promotion of brain health in a
variety of neurodegenerative disorders.
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